INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
npj Vaccines
October 2021
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
| Title | Disease Target | Product |
|---|---|---|
| Immunogenicity of a DNA vaccine candidate for COVID-19 Nature Communications — May 2020 |
COVID-19 | INO-4800 |
| 571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster Open Forum Infectious Diseases — December 2021 |
COVID-19 | INO-4800 |
| SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial The Journal of Infectious Diseases — January 2022 |
COVID-19 | INO-4800 |
| INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants npj Vaccines — October 2021 |
COVID-19 | INO-4800 |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2023 INOVIO Pharmaceuticals. All rights reserved.
